top of page

Psychedelic Reviews & Published Articles

Depression & Psychedelics

2021 narrative review of [Psychedelics] for depression.

Jelen, Luke A., and James M. Stone. “[Psychedelics] for depression.” International Review of Psychiatry 33.3 (2021): 207-228.
 

2021 international expert opinion.

McIntyre, Roger S., et al. “Synthesizing the evidence for [Psychedelics] in treatment-resistant depression: an international expert opinion on the available evidence and implementation.” American Journal of Psychiatry 178.5 (2021): 383-399.
 

2021 systematic review of 83 trials.

Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
 

2021 systematic review and meta-analysis.

Bahji, Anees, Gustavo H. Vazquez, and Carlos A. Zarate Jr. “Comparative efficacy of racemic [Psychedelics] for depression: a systematic review and meta-analysis.” Journal of affective disorders 278 (2021): 542-555.
 

2019 review.

Krystal, John H., et al. “[Psychedelics]: a paradigm shift for depression research and treatment.” Neuron 101.5 (2019): 774-778.
 

2017 consensus from the American Psychiatric Association.

Sanacora, Gerard, et al. “A consensus statement on the use of [Psychedelics] in the treatment of mood disorders.” JAMA psychiatry 74.4 (2017): 399-405.

Anxiety, PTSD, Trauma & OCD with Psychedelics 

Alan Kooi Davis, Yitong Xin, Nathan Sepeda & Lynnette A. Averill (2023) Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico, The American Journal of Drug and Alcohol Abuse, 49:5, 587-596, DOI: 10.1080/00952990.2023.2220874

2021 RCT for PTSD.

Feder, Adriana, et al. “A randomized controlled trial of repeated [Psychedelics] administration for chronic posttraumatic stress disorder.” American Journal of Psychiatry 178.2 (2021): 193-202.
 

2021 review of [Psychedelics] for PTSD and putative mechanisms.

Asim, Muhammad, et al. “[Psychedelics] For Post-Traumatic Stress Disorders And It’s Possible Therapeutic Mechanism.” Neurochemistry International (2021): 105044.
 

2021 review for addiction, OCD and eating disorders.

Martinotti, Giovanni, et al. “Therapeutic Potentials of [Psychedelics] in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
 

2020 review for the treatment of anxiety disorders.

Banov, Michael D., et al. “Efficacy and safety of [Psychedelics] in the management of anxiety and anxiety spectrum disorders: a review of the literature.” CNS spectrums 25.3 (2020): 331-342.
 

2020 review of [Psychedelics] for PTSD

Feder, Adriana, et al. “The emergence of [Psychedelics] as a novel treatment for posttraumatic stress disorder.” Advances in Pharmacology 89 (2020): 261-286.
 

2020 review for the treatment of OCD.

Sharma, Lavanya P., et al. “Clinical utility of repeated intravenous [Psychedelics] treatment for resistant obsessive-compulsive disorder.” Asian journal of psychiatry 52 (2020): 102183.

Addiction and Psychedelics

 

2022 systematic review of 83 trials.

Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
 

2021 review for alcohol use disorder.

Worrell, Stephen D., and Thomas J. Gould. “Therapeutic Potential of [Psychedelics] for Alcohol Use Disorder.” Neuroscience & Biobehavioral Reviews (2021).
 

2021 review for addiction, OCD and eating disorders.

Martinotti, Giovanni, et al. “Therapeutic Potentials of [Psychedelics] in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.” Brain Sciences 11.7 (2021): 856.
 

2021 [Psychedelics] for cannabis use disorder.

Azhari, Nour, et al. “[Psychedelics]-facilitated behavioral treatment for cannabis use disorder: a proof of concept study.” The American journal of drug and alcohol abuse 47.1 (2021): 92-97.
 

2019 RCT for cocaine dependence.

Dakwar, Elias, et al. “A single [Psychedelics] infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry 176.11 (2019): 923-930.
 

2019 RCT for cocaine use disorder.

Dakwar, E., et al. “Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist [Psychedelics]: a randomized, crossover trial.” Molecular psychiatry 22.1 (2017): 76-81.
 

2018 systematic review of [Psychedelics] for substance use disorders.

Jones, Jennifer L., et al. “Efficacy of [Psychedelics] in the treatment of substance use disorders: a systematic review.” Frontiers in psychiatry 9 (2018): 277.

Deborah C. Mash (2018) Breaking the cycle of opioid use disorder with Ibogaine, The American Journal of Drug and Alcohol Abuse, 44:1, 1-3, DOI: 10.1080/00952990.2017.1357184

Thomas Kingsley Brown & Kenneth Alper (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes, The American Journal of Drug and Alcohol Abuse, 44:1, 24-36, DOI: 10.1080/00952990.2017.1320802

Geoffrey E. Noller , Chris M. Frampton & Berra Yazar-Klosinski (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study, The American Journal of Drug and Alcohol Abuse, 44:1, 37-46, DOI: 10.1080/00952990.2017.1310218

 

Psychedelic Clinical Trials

 

2022 systematic review of 83 trials.

Walsh, Zach, et al. “[Psychedelics] for the treatment of mental health and substance use disorders: comprehensive systematic review.” BJPsych Open 8.1 (2022).
 

2021 review of neurobiological mechanisms.

Kohtala, Samuel. “[Psychedelics]—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.” Pharmacological Reports (2021): 1-23.
 

2020 safety review of 6630 patients.

Feifel, David, David Dadiomov, and Kelly C Lee. “Safety of repeated administration of parenteral [Psychedelics] for depression.” Pharmaceuticals 13.7 (2020): 151.
 

2018 blood pressure safety review.

Riva-Posse, Patricio, et al. “Blood pressure safety of subanesthetic [Psychedelics] for depression: a report on 684 infusions.” Journal of affective disorders 236 (2018): 291-297.
 

2017 review on ethics and safety.

Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). [Psychedelics] treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry, 4(5), 419-426.

Psychedelic Assisted Therapy Articles:

 

2022 on combining ACT therapy with [psychedelics].

Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward Synergies of [Psychedelics] and Psychotherapy. Frontiers in Psychology, 1203.
 

2022 systematic narrative review of [psychedelic]-assisted psychotherapy.

Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., … & Ladha, K. S. (2022). [Psychedelic] Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15, 1691.
 

2022 therapy augments effects of [psychedelics] for alcohol use disorder.

Grabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., … & Morgan, C. J. A. (2022). Adjunctive [Psychedelics] With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. The American Journal of Psychiatry, appiajp202121030277-appiajp202121030277.
 

2022 optimizing [psychedelic] treatment with trauma-informed psychotherapy.

Muscat, S. A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2022). Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating [Psychedelic] Protocols with Trauma-and Attachment-Informed Psychotherapy. Psych, 4(1), 119-141.
 

2021 therapy enhances durability of treatment effect.

Wilkinson, Samuel T., et al. “Cognitive behavioral therapy to sustain the antidepressant effects of [psychedelics] in treatment-resistant depression: a randomized clinical trial.” Psychotherapy and psychosomatics 90.5 (2021): 318-327.
 

2019 mindfulness-based therapy enhances positive effects with cocaine dependence.

Dakwar, Elias, et al. “A single [psychedelic] infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial.” American Journal of Psychiatry.

Thomas Kingsley Brown & Kenneth Alper (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes, The American Journal of Drug and Alcohol Abuse, 44:1, 24-36, DOI: 10.1080/00952990.2017.1320802

Broad Psychedelic Articles & Studies

Sarah Kratina & Leah M. Mayo (2023) Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts, The American Journal of Drug and Alcohol Abuse,49:5, 541-545, DOI: 10.1080/00952990.2023.2246637

Brittany Vasae Burdick & Bryon Adinoff (2013) A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment, The American Journal of Drug and Alcohol Abuse, 39:5, 291-297, DOI: 10.3109/00952990.2013.811513

Fernando Mendive, Cecile Giovannetti & Sara García Arce (2023) Ancient medicine for a modern disease: traditional Amazonian medicine to treat substance use disorders, The American Journal of Drug and Alcohol Abuse, 49:6, 691-704, DOI: 10.1080/00952990.2023.2264466

bottom of page